GlobeNewswire Inc | Jan 12, 2022 08:30AM EST

January 12, 2022

BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2021, ended December 31, 2021. The webcast and conference call will be held at8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time onJanuary 26, 2022.

Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovants website atinvestors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-800-532-3746 in theU.S.or +1-470-495-9166 from outside theU.S.

A replay of the webcast, along with the earnings press release and presentation materials, will be archived on Myovants investor relations website.

AboutMyovant SciencesMyovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016,Myovant has executed five successful Phase 3 clinical trials across oncology and womens health leading to two regulatory approvals by the U.S. Food and Drug Administration for men with advanced prostate cancer and women with heavy menstrual bleeding associated with uterine fibroids, respectively, as well as regulatory approvals by theEuropean Commissionand the Medicines and Healthcare products Regulatory Agency for women with symptomatic uterine fibroids. Additionally, Myovant has two regulatory submissions under review, a Marketing Authorization Application in advanced prostate cancer and a supplemental New Drug Application in endometriosis-associated pain. Myovant is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. Myovant is also developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction.Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is Myovants majority shareholder. For more information, please visitwww.myovant.com. Follow@Myovanton Twitter andLinkedIn.

Investor Contact:Ryan CroweVice President, Investor Relations+1 (650) 781-9106investors@myovant.com

Media Contact:Albert LiaoDirector, Corporate Communications+1 (650) 410-3055media@myovant.com